Trial Profile
Safety and tolerability study of farnesyl protein transferase inhibitor (FPTI) [lonafarnib, SCH 66336] in patients with leukemia
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 05 May 2022
Price :
$35
*
At a glance
- Drugs Lonafarnib (Primary)
- Indications Acute myeloid leukaemia; Chronic myeloid leukaemia; Myelodysplastic syndromes; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions
- Sponsors Merck & Co
- 21 Jul 2006 New trial record.